Risk factors for stroke and the effect of cholesterol-lowering therapy with pravastatin

被引：0
|
作者：
West, M
White, H
Simes, R
Kirby, A
Anderson, N
Hankey, G
Tonkin, A
机构：
[1] Univ Queensland, Prince Charles Hosp, Brisbane, Qld, Australia
[2] Green Lane Hosp, Dept Cardiol, Auckland 3, New Zealand
[3] NHMRC Clin Trials Ctr, Sydney, NSW, Australia
[4] Univ Auckland, Sch Med, Auckland, New Zealand
[5] Royal Perth Hosp, Clin Neurosci Div, Perth, WA, Australia
[6] Heart Fdn Australia, Melbourne, Vic, Australia
来源：
JOURNAL OF HYPERTENSION | 2000年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
引用
收藏
页码：S17 / S17
页数：1
相关论文
共 50 条
  • [1] Pravastatin: An antithrombotic effect independent of the cholesterol-lowering effect
    Dangas, G
    Smith, DA
    Unger, AH
    Shao, JH
    Meraj, P
    Fier, C
    Cohen, AM
    Fallon, J
    Badimon, JJ
    Ambrose, JA
    THROMBOSIS AND HAEMOSTASIS, 2000, 83 (05) : 688 - 692
  • [2] Pravastatin: An antithrombotic effect independent of the cholesterol-lowering effect.
    D'Agate, DJ
    Feldman, D
    Dangas, G
    Unger, A
    Shao, JH
    Meraj, P
    Fallon, JT
    Badimon, J
    Smith, DA
    Ambrose, JA
    AMERICAN JOURNAL OF CARDIOLOGY, 2000, 86 (8A): : 98I - 99I
  • [3] Effects of cholesterol-lowering therapy and antioxidant vitamin supplementation on the risk of stroke
    Collins, R
    Armitage, J
    Parish, S
    Sleight, P
    Peto, R
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (05) : 246A - 246A
  • [4] AN OVERVIEW OF TRIALS OF CHOLESTEROL-LOWERING AND RISK OF STROKE
    HEBERT, PR
    GAZIANO, JM
    HENNEKENS, CH
    ARCHIVES OF INTERNAL MEDICINE, 1995, 155 (01) : 50 - 55
  • [5] Improvement of erythrocyte deformability by cholesterol-lowering therapy with pravastatin in hypercholesterolemic patients
    Kohno, M
    Murakawa, K
    Yasunari, K
    Yokokawa, K
    Horio, T
    Kano, H
    Minami, M
    Yoshikawa, J
    METABOLISM-CLINICAL AND EXPERIMENTAL, 1997, 46 (03): : 287 - 291
  • [6] Cholesterol-lowering therapy with pravastatin in heart-transplant patients taking cyclosporine A
    Merz, M
    Park, JW
    Krell, B
    Siekmeier, R
    Marz, W
    ATHEROSCLEROSIS, 1997, 129 (01) : 28 - 28
  • [7] Increased risk for cardiovascular outcomes and effect of cholesterol-lowering pravastatin therapy in patients with diabetes mellitus in the Pravastatin Anti-atherosclerosis Trial in the Elderly (PATE)
    Ishikawa, T
    Ito, H
    Ouchi, Y
    Ohashi, Y
    Saito, Y
    Nakamura, H
    Orimo, H
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2005, 66 (01): : 48 - 65
  • [8] Effect of cholesterol-lowering therapy on endothelial function
    Houghton, JL
    CIRCULATION, 2001, 104 (02) : E6 - E6
  • [9] Will Cholesterol-Lowering Therapy Increase the Risk of Muscle Injury?
    Schneider, Philip J.
    JNP-JOURNAL FOR NURSE PRACTITIONERS, 2013, 9 (02): : 122 - 123
  • [10] Cholesterol-lowering therapy - New aspects regarding stroke and diabetes
    Riesen, WF
    SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT, 1998, 128 (1-2) : 26 - 27
12345